Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

  • Antonia Sambola
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Julio Osende
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • James Hathcock
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Michael Degen
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Yale Nemerson
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Valentin Fuster
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Jill Crandall
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.
  • Juan Jose Badimon
    From the Cardiovascular Biology Research Laboratory (A.S., J.O., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (A.S., J.O., V.F.), Division of Thrombosis (J.H., M.D., Y.N.), and Division of Endocrinology (J.C.), Mount Sinai School of Medicine, New York, NY.

説明

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Several studies suggest a role for an increased circulating pool of tissue factor (TF) in atherothrombotic diseases. Furthermore, certain cardiovascular risk factors, such as diabetes, hyperlipemia, and smoking, are associated with a higher incidence of thrombotic complications. We hypothesized that the observed increased blood thrombogenicity (BT) observed in patients with type 2 diabetes mellitus may be mediated via an increased circulating tissue factor activity. We have extended our study to smokers and hyperlipidemic subjects. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Poorly controlled patients with type 2 diabetes mellitus (n=36), smokers (n=10), and untreated hyperlipidemic subjects (n=10) were studied. Circulating TF was immunocaptured from plasma, relipidated, and quantified by factor Xa (FXa) generation in the presence of factor VIIa. BT was assessed as thrombus formation on the Badimon perfusion chamber. Patients with improvement in glycemic control showed a reduction in circulating TF (362±135 versus 243±74 pmol/L per min FXa, <jats:italic>P</jats:italic> =0.0001). A similar effect was observed in BT (15 445±1130 versus 12 072±596 μm/mm <jats:sup>2</jats:sup> , <jats:italic>P</jats:italic> =0.01). Two hours after smoking 2 cigarettes, TF was increased (217±72 versus 283±106 pmol/L per min FXa, <jats:italic>P</jats:italic> =0.003). Hyperlipidemic subjects showed higher TF (237±63 versus 195±44 pmol/L per min FXa, <jats:italic>P</jats:italic> =0.035) than healthy volunteers. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> These findings suggest that high levels of circulating TF may be the mechanism of action responsible for the increased thrombotic complications associated with the presence of these cardiovascular risk factors. These observations strongly emphasize the usefulness of the management of the patients based on their global risk assessment. </jats:p>

収録刊行物

  • Circulation

    Circulation 107 (7), 973-977, 2003-02-25

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ